Locations:
Search IconSearch
February 15, 2022/Cancer

Let’s Talk About Childhood Cancer Survivorship (Podcast)

Seth Rotz, MD, joins the Cancer Advances podcast to share insights

Pediatric cancer survivor

More children are surviving childhood cancers than ever before. Each year in the United States about 15,000 children are diagnosed with cancer, and about 80% to 85% will survive five years or longer.

Advertisement

Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy

While these numbers are encouraging, pediatric oncologists say a shift to better longer-term management of pediatric cancer survivors is warranted. The Childhood Cancer Survivorship Program at Cleveland Clinic Children’s is focused on doing just that.

Led by pediatric hematologist/oncologist Seth Rotz, MD, the physicians work with pediatric cancer survivors, their families, and other subspecialists as needed to identify risks and monitor late effects associated with disease and its treatment. They also provide counsel and resources related to other concerns, such as family planning and psychosocial issues.

Dr. Rotz joined the Cancer Advances podcast to discuss the goals of the program, the biggest issues in childhood cancer survivorship programs, and the next exciting thing in the field.

An excerpt from the podcast

“Our focus in cancer survivorship has focused a great deal on the medical effects of having received chemotherapy and radiation. And, I think, in the last several years, there’s just been more attention focused on questions like: What are the long-term psychological impacts? What are the financial impacts of having had cancer? Does this impact whether a teenager ends up applying to college or not? Or does it put somebody in a position where they can’t change jobs because they’re worried about health insurance coverage and so forth,” he says.

“And then we have so many people and parents, too, who have some degree of post-traumatic stress from their treatment, and so we are trying to identify different mental health issues that can go along with treatment and get people plugged in with the resources they need, which is another very important part of what we do.”

Advertisement

Featured in Cleveland Clinic Children's 2022 Year in Review

Advertisement

Related Articles

Dr. Tendulkar
July 21, 2025/Cancer/News & Insight
Radiation Therapy Effective for Treating Benign Proliferative Disease of the Extremities

Noninvasive treatment may slow progression of Dupuytren's disease and plantar fibromatrosis

Older patients
July 17, 2025/Cancer/News & Insight
CAR T-Cell Therapy Safe & Effective for Octogenarians with B-Cell Lymphoma

Age alone should not rule out patients from potentially curative treatment

Surgeon
June 30, 2025/Cancer/News & Insight
Potential for Deintensification of Surgical Interventions in Low-Risk Breast Cancer

Reconsidering axillary lymph node dissection as well as depth of surgical margins

Dendritic cell
June 26, 2025/Cancer/News & Insight
Avelumab Induces Natural Killer Cell Activation and Dendritic Cell Crosstalk

Researchers uncover profound differences in the mechanism of action between different PD-L1 checkpoint inhibitors

World map
June 19, 2025/Cancer/News & Insight
Breaking Barriers to Cancer Care: Cleveland Clinic’s Global Approach

A multi-pronged strategy for tackling cancer access problems

CAR T-cell therapy illustration
June 12, 2025/Cancer/News & Insight
First-Ever U.S. Trial of CAR T-Cell Therapy for Relapsed/Refractory AL Amyloidosis

Early results show patients experiencing deep and complete response

Genomic profiling
June 10, 2025/Cancer
Cleveland Clinic’s Hemato-Oncology Team Spearheads the Development of Guidelines for Genomic Profiling of MDS to Inform Allo-HCT

Inclusion of genomic profiling and risk factors recommended for treatment planning

scan showing cholangiocarcinoma
June 5, 2025/Cancer/News & Insight
Exploring Novel Therapeutic Avenues in Advanced Cholangiocarcinoma: Lessons from the EA2187 Trial

Collaborative research effort underscores the urgent need for effective second-line therapies in this rare, aggressive cancer

Ad